Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Thyroid cancer
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 74 for your search:
Start Over
Total Thyroidectomy With Harmonic Scalpel®
Phase: Phase IV
Type: Health services research, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: CP005, NCT00385983
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-003, NCT00902122
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-401, NCT01896479
Radiolabeled Molecules for Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: Lu177-med, NCT01915485
Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2009-02-017, NCT01149161
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UCL/10/0299, 2011-000144-21, Cancer Research UK, ISRCTN, NCT01398085
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: NCCCTS13-671, 1410650-1,2, NCT02418247
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2008-09-048, NCT00795782
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00065, EudraCT 2013-000423-14, NCT01843062
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-A01569-34, 2012/1913, NCT01837745
Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: B-1403/242-006, NCT02112370
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 90
Sponsor: NCI
Protocol IDs: 110027, 11-C-0027, NCT01240590
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specifiec
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHSC835X2202, NCT01930162
BNCT and IG-IMRT for Recurrent Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18 to less than 80 years
Sponsor: Other
Protocol IDs: 2012-06-016A, NCT02004795
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 150090, 15-C-0090, NCT02390739
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PLX120-03, NCT02428712
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to less than 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-207, 2013-005534-38, NCT02432274
Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Panthera, NCT00786552
DOTA-TOC in Metastasized Neuroendocrine Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MAW002, NCT00978211
Study of External Beam Radiotherapy to Thyroid Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NCCCTS-09-436, NCT01173289
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 100041, 10-C-0041, NCT01182285
Start Over